Vis enkel innførsel

dc.contributor.authorRustad, Even Holth
dc.contributor.authorHultcrantz, Malin
dc.contributor.authorYellapantula, Venkata D
dc.contributor.authorAkhlaghi, Theresia
dc.contributor.authorHo, Caleb
dc.contributor.authorArcila, Maria E
dc.contributor.authorRoshal, Mikhail
dc.contributor.authorPatel, Akshar
dc.contributor.authorChen, Denise
dc.contributor.authorDevlin, Sean M
dc.contributor.authorJacobsen, Austin
dc.contributor.authorHuang, Ying
dc.contributor.authorMiller, Jeffrey E
dc.contributor.authorPapaemmanuil, Elli
dc.contributor.authorLandgren, Ola
dc.date.accessioned2022-05-03T08:21:56Z
dc.date.available2022-05-03T08:21:56Z
dc.date.created2020-03-19T12:30:44Z
dc.date.issued2019
dc.identifier.citationPLOS ONE. 2019, 14 (3), 1-17.en_US
dc.identifier.issn1932-6203
dc.identifier.urihttps://hdl.handle.net/11250/2993777
dc.description.abstractTracking of clonal immunoglobulin V(D)J rearrangement sequences by next generation sequencing is highly sensitive for minimal residual disease in multiple myeloma. However, previous studies have found variable rates of V(D)J sequence identification at baseline, which could limit tracking. Here, we aimed to define the factors influencing the identification of clonal V(D)J sequences. Bone marrow mononuclear cells from 177 myeloma patients underwent V(D)J sequencing by the LymphoTrack assays (Invivoscribe). As a molecular control for tumor cell content, we sequenced the samples using our in-house myeloma panel myTYPE. V(D)J sequence clonality was identified in 81% of samples overall, as compared with 95% in samples where tumor-derived DNA was detectable by myTYPE. Clonality was detected more frequently in patients with lambda-restricted disease, mainly because of increased detection of kappa gene rearrangements. Finally, we describe how the tumor cell content of bone marrow aspirates decrease gradually in sequential pulls because of hemodilution: From the initial pull used for aspirate smear, to the final pull that is commonly used for research. In conclusion, baseline clonality detection rates of 95% or higher are feasible in multiple myeloma. Optimal performance depends on the use of good quality aspirates and/or subsequent tumor cell enrichment.en_US
dc.language.isoengen_US
dc.publisherPublic Library of Scienceen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleBaseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myelomaen_US
dc.title.alternativeBaseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myelomaen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber1-17en_US
dc.source.volume14en_US
dc.source.journalPLOS ONEen_US
dc.source.issue3en_US
dc.identifier.doi10.1371/journal.pone.0211600
dc.identifier.cristin1802421
dc.relation.projectNorges forskningsråd: 223255en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal